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Abstract- Prevalence and correlates of anxiety disorders in psychotic illness 
Background: Comorbid anxiety disorders in psychotic illness are reported in the international 
literature as highly prevalent and have a significant negative impact on patient outcomes. Local 
literature describing such comorbidity in the South African population is limited and clinically, 
anxiety symptoms are seldom recognised or treated in patients with psychotic disorders. More data 
on prevalence rates across psychotic disorder diagnoses, as well as sociodemographic correlates 
would aid recognition, diagnosis, and treatment, and potentially improve clinical outcomes in this 
population. 
Method: We performed a secondary analysis of an existing database which comprised data from 
participants of three previous studies. The sample was made up of patients from Valkenberg Hospital 
and healthcare facilities in its catchment area. All patients had a diagnosis of a psychotic disorder. 
Socio-demographic information was collected using a structured questionnaire. Clinical information 
and diagnosis was determined using the Structured Clinical Interview for DSM (SCID-I).  Rates of 
comorbid anxiety disorders were compared across various sociodemographic categories. 
Results: The overall prevalence of any anxiety disorder in the entire sample (N=226) was 14.6% (n=33), 
95% CI [10.27-19.89%]. The most common anxiety disorder comorbidities were, in descending order, 
panic disorder (n=12, 5.31%; 95% CI [2.77-9.09%]), PTSD (n=9, 3.98%; 95% CI [1.84-7.42%]), specific 
phobia (n=7, 3.10%; 95% CI [1.25-6.28%]), anxiety disorder not otherwise specified (n=7, 3.10%; 95% 
CI [1.25-6.28%]), social phobia (n=4, 1.77%; 95% CI [0.48%-4.47%]), generalised anxiety disorder (n=4, 
1.77%; 95% CI [0.48-4.47%]), substance-induced anxiety disorder (n=4, 1.77%; 95% CI [0.48-4.47%]) 
and obsessive compulsive disorder (n=2, 0.88%; 95% CI [0.11-3.16%]). There was a significant 
association between diagnosis and the presence of post-traumatic stress disorder (PTSD), with the 
schizoaffective disorder group having a higher rate of PTSD (13.3% vs. 3.3% in schizophrenia, 3.2% 
in substance-induced mood/psychotic disorder and 0% in bipolar I disorder) (Fisher’s exact test, 
p=0.039). In turn, there was a trend level association between diagnosis and the presence of panic 
disorder (PD), with schizoaffective disorder patients having higher rates of PD (16.6% vs. 4.1% in 
schizophrenia spectrum, 3.2% in substance-induced mood/psychotic disorder and 2.2% in bipolar I 
disorder) (Fisher’s exact test, p=0.052).  
5 
 
A significant association was found between level of education and the presence of PTSD, with higher 
rates of PTSD in patients with seven or less years of education (8.8%) compared to lower rates in those 
with 8-12 years of education (5.3%) and > 12years of education (0%) (Fisher’s exact test, p=0.020).  
Conclusion: The overall prevalence of anxiety disorders in psychotic illness was lower than what has 
been described in previous literature. Prevalence rates of individual anxiety disorders were also lower 
than previously published literature.  Possible reasons for this include use of the SCID which utilises 
a strict diagnostic hierarchy, that the majority of the sample were in-patients, no use of self-report 
questionnaires or other anxiety-specific diagnostic instruments, or possible geographical and/or 
ethnic differences in South African patients. The most frequent comorbid anxiety disorders in our 
study were panic disorder and PTSD. This is out of keeping with other literature which has mostly 
found obsessive compulsive disorder and social anxiety disorder to be the most common anxiety 
comorbidities in psychotic illness. Further research into comorbid anxiety in psychotic disorders is 
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Chapter I: Introduction and Literature review  
 
1. Literature search strategy  
A literature search was performed on the Medline database through the PubMed portal using 
combinations of the following terms: 
"schizophrenia",  “schizophreniform disorder” or “schizophreniform”, "psychotic disorder" or 
“psychosis”, "schizoaffective disorder" or “schizoaffective”, “bipolar disorder" or “bipolar”, 
“substance-induced psychosis” or “substance-induced psychotic disorder” or drug-induced 
psychosis” or “drug-induced psychotic disorder”, “anxiety” or “anxiety disorder”, “generalised 
anxiety disorder” or “GAD”, "post-traumatic stress disorder" or “PTSD”,  “obsessive-compulsive 
disorder" or “OCD”, "panic disorder" or “panic”, “phobia” or "phobic disorders”, “social anxiety 
disorder” or “social phobia”.  
 
The search was confined to literature in English and only systematic reviews and meta-analyses 
from the last 20 years were included. A total of 895 papers were identified, the titles of which were 
scanned to identify relevant studies, which totalled 37. Additional studies were identified using the 
reference lists of the papers generated from the original search. 
 
2. Summary of the Literature 
2.1. Introduction 
Symptoms of anxiety in psychotic illness have long been recognised and were even described by 
Bleuler.1  Although there has been a recent increase in literature looking at this topic, data is still 
limited and the studies that have been done vary widely in both methodology and outcomes, 
making analysis of results difficult. 2–4 
 
It remains unknown whether anxiety in psychotic illness should be viewed as secondary symptoms 
that occur due to the distressing nature of psychosis, as a comorbidity that occurs as a result of 
chance or shared risk factors, or whether anxiety features represent part of a prodromal picture or 
different symptom dimension of the core condition.5  As a further complicating factor, some 
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neuroleptic drugs used in psychotic disorders have been associated with treatment-emergent 
anxiety symptoms.6–9 
 
Diagnosis of a comorbid anxiety disorder in people with psychotic illness may be complicated by 
the hierarchical structure found in diagnostic systems such as the Diagnostic and statistical manual 
of mental disorders (DSM).10,11   The way in which the DSM has been structured, is to prioritise 
certain groups of disorders over others. For example, in diagnostic criteria for anxiety disorders, the 
DSM requires that the symptoms are “not better accounted for by another mental disorder”.10  This 
makes diagnosis of an anxiety disorder difficult and often subjective as, even if all the other criteria 
for the disorder are fulfilled, it is necessary to decide whether the anxiety symptoms may be 
accounted for by the primary psychotic diagnosis or not. This has probably led to low rates of 
diagnosis and recognition of anxiety disorders in schizophrenia in the past.12  Diagnostic hierarchies 
have also complicated research as some studies suspend diagnostic hierarchies in their 
methodologies and others do not.  
 
Clinically, perhaps due not only to diagnostic hierarchies but also because of the dramatic nature of 
psychotic symptoms, anxiety seems to be seldom recognised, diagnosed or treated in psychotic 
patients as the psychotic symptoms demand the bulk of clinical attention.  
 
In the literature that is available on anxiety in psychotic illness, prevalence rates are heterogeneous 
but generally high, often higher than in the general population.2–4,9  This is of concern as, not only 
are anxiety disorders themselves disabling and potentially life threatening, but comorbid anxiety in 
psychotic illness seems to have significant negative effects on outcomes. These effects include 
decreased levels of social functioning, poorer quality of life, increased suicide risk, higher risk of 
relapse and poorer treatment response in psychotic illnesses. 13 
 
With better understanding of anxiety in psychotic illness, increased recognition and treatment could 
potentially improve outcomes in affected individuals. Moreover, as patterns of comorbidity are 





2.2. Anxiety and psychosis 
Most data have looked at anxiety in specific psychotic disorders. However two major studies 
measured prevalence of anxiety disorders across several psychotic disorder diagnoses.13,14 
Both found high rates of anxiety disorders across the different psychotic disorders. Cosoff et al14 
found similar prevalence rates (43-45%) of anxiety disorders in schizophrenia (SCZ), schizoaffective 
disorder (SZA) and bipolar disorder (BPD). In a study by Young et al13, significant differences of 
comorbid anxiety were found between the psychotic disorders, with the highest rate of anxiety 
disorders in schizoaffective disorder (30.1%), followed by BPD (22.4%) and then schizophrenia 
(16.7%). The authors hypothesised that higher prevalence in SZA may be associated with more 
mood features. When assessing rates of each anxiety disorder (AD), panic disorder was found to co-
occur most commonly with a psychotic disorder.13  Some gender differences (Female > male), a low 
rate of clinical recognition and a higher rate of AD in those with a family history of anxiety 
disorders were noted.13,14 
 
Across the literature of anxiety in psychotic illness, broad variations in results exist. Several possible 
reasons for this have been suggested. These include: heterogeneity in definitions and sampling 
methods, small sample sizes and different ratings instruments or diagnostic methods used.2,5  In 
addition, the diagnostic hierarchy and whether this has been suspended or not, is another likely 
source of heterogeneity in the data.2,9  
 
There is currently very little understanding of the relationship between psychotic disorders and 
anxiety. Several hypotheses have been presented including: anxiety as the primary disorder, as a 
comorbid disorder or caused by treatment for psychosis.15  
 
One potential outcome of improved understanding of the relationship between psychosis and 
anxiety is discovery of common pathophysiological processes. Dysregulation of dopamine, 
serotonin and glutamate systems are known to be involved in both psychotic and anxiety 
disorders.16 Preliminary findings regarding comorbidity of anxiety and schizophrenia, implicate 
both serotonin transporter (SERT) and brain-derived neurotrophic factor (BDNF) genes as well as 
the serotonin-1A (5HT1A) receptor.9  In addition, there is some early data from patients with 
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schizophrenia and anxiety disorders that describe under-active fear circuitry in response to anxiety-
provoking stimuli coupled with heightened autonomic response to neutral stimuli.9   
 
2.3. Schizophrenia spectrum and anxiety 
International data show a high prevalence of anxiety disorders in schizophrenia, with good 
evidence to indicate that these rates may be higher than the general population.2  Though significant 
heterogeneity of the data exists, prevalence of anxiety symptoms in schizophrenia are thought to 
occur in up to 65% and prevalence of anxiety disorders, diagnosable in up to 38%.2,9  Social anxiety 
disorder (SAD) appears to be the most common comorbid anxiety disorder in schizophrenia, 
followed by post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), 
generalised anxiety disorder (GAD), panic disorder (PD), simple phobia and agoraphobia.9 
 
Diagnosis of anxiety in the context of schizophrenia may prove difficult for a number of reasons. 
Firstly, positive and negative symptoms of psychosis may make it difficult to identify signs and 
symptoms of anxiety.17  Positive psychotic symptoms such as delusions, disorganisation and 
hallucinations may overshadow the presentation of anxiety. Negative symptoms including 
decreased emotional expression may prevent clear communication and lead to under-reporting or 
detection of such symptoms. Finally, both agitation related to psychosis and akathisia (an effect of 
treatment) may mimic anxiety and make differentiation between the diagnoses more challenging.9,17 
 
In order to improve diagnostic accuracy, recommendations include assessment after the acute phase 
of psychosis has settled, routine use of screening questions for anxiety symptoms and employment 
of self-report instruments.9  Specialised rating scales may also aid detection and severity assessment 
of anxiety disorders in schizophrenia.16 
 
In a recent meta-analysis, the prevalence rates of comorbid anxiety disorders were found to be 
higher in women with schizophrenia, in out-patient settings and when Structured Clinical Interview 
for DSM-IV-TR18 (SCID) or additional instruments were used to diagnose anxiety disorders.2   
 
Comorbid anxiety disorders appear to have overall negative effects on the functioning, response to 
treatment and quality of life of patients with SCZ.2,15  Comorbid anxiety has been linked with 
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increased severity of psychopathology 5,  increased suicidality, more cognitive impairment, more 
social withdrawal, poorer functioning, increased likelihood of treatment changes and increased use 
of services.9,15,19   
 
Data regarding treatment of anxiety in schizophrenia is very limited. There is some evidence for the 
usefulness of risperidone and aripiprazole in obsessive-compulsive symptoms (OCS) and social 
anxiety. For GAD, some efficacy of quetiapine and olanzapine has been shown. In addition, there is 
also data to support the use of trifluoperazine, a first generation antipsychotic, for treating anxiety 
symptoms in schizophrenia. Other treatment options that have been investigated but for which 
there is little data so far, include the augmentation of antipsychotic medication with selective 
serotonin reuptake inhibitors (SSRI’s), buspirone and pregabalin.9  
 
2.3.1. Schizophrenia Prodrome 
Anxiety may form part of the prodrome of schizophrenia. In a review of prodromal symptoms of 
psychosis, Yung and McGorry found that anxiety and obsessive compulsive symptoms are common 
in this period.20 One large study of patients assessed as having an at-risk mental state (ARMS) 
showed that 69% of patients had a diagnosis of a mood or anxiety disorder at the time of initial 
assessment.21  A meta-analysis (MA) of the literature on ARMS patients found that, in addition to 
attenuated psychotic symptoms, 15% of ARMS patients had a comorbid anxiety disorder at baseline 
assessment.22  In addition, this MA found that comorbid diagnoses of anxiety or depressive 
symptoms in ARMS were associated with higher levels of disorganised behaviour, more suicidality 
and self-harm as well as impaired global functioning, worse apathy and avolition.22  However, no 
effect of baseline anxiety or depressive diagnosis on the rate of transition to frank psychotic illness 
was identified.22 
 
In terms of phenomenology, it is unclear whether these anxiety symptoms represent features of a 
comorbid illness or early symptoms of the psychotic disorder. Moreover, current data does not yet 






2.3.2. Schizophrenia and panic 
Both panic attacks and panic disorder appear to co-occur commonly with schizophrenia.2,5  The 
pooled prevalence rate of panic disorder in a recent meta-analysis was 9.8%.2 
 
As with other anxiety disorders, the relationship between panic disorder and schizophrenia remains 
unclear.16   Some authors have argued that it may represent a specific subtype of schizophrenia with 
its own pattern of clinical symptoms, deficits and response to treatment.12 
 
There is limited of data on treatment of panic symptoms in schizophrenia. Some early data suggests 
efficacy of alprazolam and clonazepam.12 
 
2.3.3. Schizophrenia and social phobia 
Social anxiety disorder or social phobia appears to be one of the most prevalent anxiety disorders in 
people with schizophrenia. Reported prevalence rates vary between 3.6 and 39.5% but in their meta-
analysis, Achim et al found a pooled prevalence rate of 14.9%.2 
 
Symptoms of schizophrenia and social anxiety disorder may appear superficially similar which can 
complicate diagnosis.12,16  The Liebowitz social anxiety scale has been used as an aid in diagnosis 
and has been found to be a reliable assessment tool in patients with schizophrenia.23  Both disorders 
may present with poor social functioning, avoidance, social withdrawal and excessive concerns 
about negative judgements by others.12,16 
 
2.3.4. Schizophrenia and obsessive compulsive disorder 
OCD is the most studied comorbid anxiety disorder in schizophrenia.5  Prevalence of OCS in 
schizophrenia is estimated at 30.3%8 and of OCD 12.1%.2  
 
The comorbid diagnosis of OCD has been associated with greater disability15, younger age at onset 
of illness, increased rates of hospitalisation, decreased likelihood of being married or employed24, 
greater risk of suicidal ideation and attempts25, more positive and negative psychotic symptoms6,  
greater paranoia and first rank symptoms, increased rates of depression and comorbid personality 
disorder,26  poorer quality of life and greater social and occupational impairments.27,28  In addition, 
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some studies have found more severe neuropsychiatric impairments in patients with OCD and 
schizophrenia, particularly in certain domains of executive function.5,29  
 
Some data suggest that when OCS are treated successfully, symptoms of psychosis also improve.30  
Which treatment is the most efficacious and appropriate in this population remains uncertain.  
 
Paradoxically, although second generation antipsychotic drugs can be effective in treatment of 
refractory OCD, they appear to have potential to worsen OCS in patients with schizophrenia, and 
sometimes even cause de novo OCS.5 Nonetheless, some data shows that clozapine and olanzapine 
may improve psychotic and obsessive-compulsive symptoms in certain patients with both.31 
 
In terms of the potential neurobiological basis for comorbid schizophrenia and obsessive 
compulsive disorder, it is known that both involve serotonin and dopamine neurotransmitter 
systems, and that particular structures of the brain are implicated in both disorders, including 
prefrontal cortex, the anterior cingulate cortex, caudate nucleus, and thalamus.5,31  More research is 
needed to elucidate further details. 
 
Some authors argue that data which shows specific characteristics of psychopathology, treatment 
response and course of illness related to individuals with schizophrenia and OCD, may suggest an 
obsessive subtype of schizophrenia (“schizo-obsessive” subtype) rather than two comorbid 
conditions.5,31  
 
Because of the high prevalence and far-reaching clinical consequences of comorbid OCD and OCS in 
schizophrenia, some recommend routine evaluation for OCS in schizophrenia patients.8   
 
2.3.5. Schizophrenia and post-traumatic stress disorder  
Comorbidity of schizophrenia and PTSD have been conceptualised in some studies as PTSD with 
psychotic symptoms and in others as psychotic illness with comorbid PTSD. Clinically and in 
research, difficulties may arise in differentiating between these two conditions as there are 
similarities in some symptoms (e.g. hallucinations versus flashbacks) and both conditions share 
certain risk factors.32  In both disorders, there is a distinction between positive symptoms, such as 
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hallucinations and flashbacks; and negative symptoms such as decreased emotional expression, 
social isolation and a feeling of detachment from others.5,32 
 
Also, there is some controversy about whether psychosis itself- like the frightening experiences of 
delusions and hallucinations- or related experiences like hospitalisation and seclusion can count as 
trauma that leads to PTSD.5  
 
The reported prevalence of PTSD in psychosis has ranged widely from 0-67%.5  The pooled 
prevalence of PTSD in schizophrenia has been estimated at 12.4%.2  
 
Risk factors that have been identified for PTSD in schizophrenia include female gender, substance 
use, repeated or ongoing traumatic experiences and early-life trauma.16 
 
Buckley et al argue that high rates of PTSD may be mostly related to increased rates of early 
exposure to trauma or as a result of psychosis-related trauma.5  Grubaugh et al suggest that a 
bidirectional relationship exists between trauma and serious mental illness, with psychiatric 
symptoms increasing risk of victimisation and this trauma then causing further psychiatric 
symptoms and impairment.33 
 
Schizophrenia with comorbid PTSD has been associated with worse symptoms of psychopathology, 
increased service use5, higher rates of depression32 and suicidality5, more positive symptoms, worse 
psychosocial functioning and quality of life.32 
  
Data on neurobiological factors associated with PTSD in schizophrenia is lacking.5  Both 
schizophrenia and PTSD have been associated with structural abnormalities in specific parts of the 
brain e.g. frontal lobe.34,35  Differences in smooth pursuit eye movement deficits in schizophrenia 
compared to PTSD with psychotic symptoms may suggest differences in underling neurobiology, 
but replication is needed.16 
 
Other hypotheses include that dopamine hypofunction in patients with comorbid schizophrenia 
and PTSD may lead to increased firing of the locus ceruleus, more noradrenalin activity and 
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subsequent increase in levels of arousal.16  Seedat et al have suggested that the exposure of neural 
networks to trauma (particularly the noradrenergic system and hypothalamic-pituitary axis), may 
cause susceptibility to both schizophrenia and PTSD.36 
 
According to Buckley5, there have been no published genetic or family studies on PTSD in 
schizophrenia, and one twin study by Lyons et al  showed no significant results.37 
  
In terms of treatment, little consensus on appropriate pharmacological or non-pharmacological 
management of PTSD in psychotic illness has been reached so far.  
 
2.4. Bipolar disorder and anxiety 
As with schizophrenia, a high prevalence of anxiety disorders has been found in bipolar disorder 
and comorbid anxiety has been associated with worse outcomes.4   
 
Two recent meta-analyses found similarly high prevalence rates of anxiety disorders in BPD, 
ranging from 42.7-45% lifetime prevalence.4,38  The most common anxiety disorders co-occurring 
with BPD appear to be GAD (14.4-20%), SAD (13.3-20%), panic disorder (16.8-19%), PTSD (10.8-
17%), OCD (10.7%), specific phobia (10.8%) and agoraphobia (7.8%).4,38   
 
Comorbid anxiety disorders in bipolar disorder have been associated with increased suicidality, 
substance abuse, more mood episodes of increased severity, prolonged recovery time, poorer 
response to lithium, worse treatment side-effects, earlier age of onset of bipolar disorder, decreased 
quality of life, worse overall course of illness and impairment in functioning with continued 
functional impairment between mood episodes.4,38–43  
 
Some suggested explanations for the high rate of comorbid anxiety disorders in bipolar disorder 
include common genetic susceptibility, common risk factors e.g. trauma or a stressful life event, the 
co-occurrence of anxiety symptoms with depressive episodes, or low self-esteem as another possible 




2.5. Schizoaffective disorder and anxiety 
Few studies have looked at anxiety in SZA specifically. It has been included in some literature 
under the umbrella-term of schizophrenia-spectrum disorders. In others, comorbid anxiety 
disorders in SZA have been examined alongside other psychotic disorder diagnoses. Young et al 
estimates the prevalence of comorbid anxiety disorders in SZA to range from 32-45%.13  In the same 
study, comorbid anxiety disorders were found to be more frequent in SZA than in BPD or 
schizophrenia. The authors proposed that this may be based on an association with affective 
symptoms found in SZA. 
 
2.6. Substance-induced psychotic disorder and anxiety 
Very little data were found regarding comorbidity of AD in substance-induced psychotic disorders. 
Only one study was identified which assessed 121 patients with methamphetamine-induced 
psychosis for anxiety symptoms.44  This article reported 3.3% comorbidity with anxiety as measured 
by the Hamilton anxiety scale (HAM-A)45  and 24.8% with OCD as measured by the Yale-Brown 
obsessive compulsive scale (Y-BOCS) .46 
 
2.7. Treatment-emergent anxiety symptoms 
Although anti-psychotic drugs can be used to treat anxiety disorders in patients without psychotic 
disorder16, these same medications appear to have the potential to worsen anxiety symptoms or 
even precipitate the onset of new anxiety symptoms in patients with psychotic illness.9,16  This 
phenomenon seems to occur particularly during early phases of treatment, in younger patients, in 
males and in individuals with shorter duration of psychosis. Treatment-emergent social anxiety and 
obsessive compulsive symptoms appear to be associated with second-generation antipsychotics, 
particularly clozapine.9,16  
 
2.8. Local literature 
There is very little local data on anxiety in psychotic illness. Only three African studies were 
identified on the topic of anxiety in schizophrenia-spectrum disorders 17,47,48 and four others which 




Emsley et al assessed a group of patients with schizophrenia/schizophreniform disorder for 
symptoms of depression and anxiety.53  These were found to be lower than expected in comparison 
to previous literature. The authors hypothesised that this may have been because of the exclusion of 
schizoaffective disorder. In this study, depression and anxiety symptoms were more common in 
women, in first-episode psychosis and in patients with more positive psychotic symptoms.  
 
A later South African study of anxiety in schizophrenia, assessed in-patients a week before 
discharge using a clinical interview, several diagnostic questionnaires and rating scales.17  A total of 
22.9% of this sample met diagnostic criteria for one or more anxiety disorder on the Mini 
International Neuropsychiatric Interview.54  The most commonly diagnosed anxiety disorder was 
GAD (8.6%; n=6), followed by SAD (5.7%, n=4), OCD (4.3%, n=3) and PTSD (4.3%, n=3).  
 
One other African study on comorbid anxiety disorders in patients with schizophrenia was found, 
from Nigeria.48  This study used a larger sample (n=367) and found a lower prevalence overall, with 
the rate of anxiety disorders in their sample being 12.3%. The individual anxiety disorders 
measured were also slightly less prevalent, GAD having a 6.3% prevalence, OCD 3.3% and phobic 
anxiety disorder 2.7%.  
 
Four African studies on OCD/OCS in psychotic illness were identified.49–52  Three of these were 
South African and one Kenyan. The two South African studies that were not limited to Caucasian 
participants49,50 (Xhosa speaking participants in Niehaus et al, participants of mixed ethnicity in 
Koen et al) found particularly low prevalence of OCD/OCS in SCZ. (0.5-1.1%). The South African 
study which was limited to Afrikaner participants55, as well as the Kenyan study52, found OCS/OCS 
rates more in keeping with international literature (12.2-13.2%). These authors hypothesise that 
certain ethnic or cultural factors may be protective against such comorbidity. An alternative 
explanation may be related to language and cultural factors affecting conceptual understanding and 
differentiating between obsessions and delusions.8 
  
2.9. Conclusion 
Comorbidity of anxiety disorders appears to be common, though under-recognised. Having an 
additional diagnosis of an anxiety disorder negatively affects prognosis and outcomes in a variety of 
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domains, as well as reducing quality of life. Although certain comorbidities have been examined 
more closely than others in the literature, there remains an overall lack of data on this clinically 
important topic. Understanding of the relationship between and neurobiological mechanisms 
underlying co-occurring anxiety and psychosis remains limited.  
 
Various factors in research to date have caused heterogeneous data which is not easily comparable. 
In addition, diagnosis may be complicated in both clinical and research settings due to several 
factors. 
 
Although some early data into possible pharmacological and psychotherapeutic treatment options 
exist, this is not yet adequate to inform clear clinical guidelines. 
 
3. Limitations of the literature and motivation for this study 
Literature on anxiety disorders in psychotic illness remains deficient in many areas and generally 
heterogeneous. Particular areas that are lacking include longitudinal data which examine 
chronological relationships between anxiety, psychosis and psychotic prodrome, course of illness, 
response to treatment and outcomes. Further research into neurobiological mechanisms underlying 
the comorbid disorders may help to improve understanding of the psychopathology, inform future 
diagnostic categories and guide treatment approaches. Studies that compare comorbid anxiety 
disorders across psychotic diagnosis categories may aid in clarifying these specific relationships and 
focussing attention on the anxiety disorders that occur commonly in relation to a specific psychotic 
illness. Comorbidity of anxiety disorders in substance-induced psychotic disorders remains largely 
unexplored.  
 
More randomised control trials are needed into drug management as well as further exploration of 
non-pharmacological interventions to establish what constitutes optimal management for this 
population. Development of more standardised instruments for screening and quantification of 
anxiety symptoms in psychosis may aid accurate diagnosis. More standardisation of sampling and 
other aspects of methodology in future studies will improve comparability and reduce the 




In the local context, there is a lack of South African data. More studies in South Africa are important 
because anxiety disorders have been found to be highly prevalent in the general population and 
may be affected by ethnic and cultural factors as well as high levels of violence and trauma in our 
society. 
 
The aim of this study is to examine prevalence of anxiety disorders in psychotic illness in a local, 
South African context with specific focus on cross-diagnostic comparison and examination of 
potential socio-demographic correlates of this comorbidity. More data of this type may help to 
inform clinical practises including clinician-awareness, screening, accurate diagnosis and 
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1. Introduction 
Symptoms of anxiety in psychotic illness have long been recognised and were even described by 
Bleuler.1,2  Although there has been some recent increased interest in this topic, there is still a lack of 
data in this area and the studies that have been done vary widely in both methodology and 
outcomes, making analysis of results difficult.3–5  
 
International data show a high prevalence of anxiety disorders (AD) in individuals with psychotic 
illnesses including schizophrenia (SCZ), schizoaffective disorder (SZA) and bipolar disorder 
(BPD).3,5,6  One recent meta-analysis indicated that up to 38.3% of subjects with schizophrenia also 
suffered from at least one AD.3  Social anxiety disorder (SAD), post-traumatic stress disorder (PTSD) 
and obsessive compulsive disorder (OCD) were the most common disorders. Literature on anxiety 
comorbidities in BPD also report high prevalence rates.5,6 
 
In a study by Young et al, which included schizophrenia, bipolar disorder and schizoaffective 
disorder, high rates of anxiety disorders were found in all three psychotic disorder diagnoses.7  The 
rates of AD were highest in the SZA group with a prevalence of 30.1%. In BPD and SCZ the rates were 
22.4% and 16.7% respectively. A few small studies of patients with first episode psychosis and 




Very little data is available regarding the comorbidity of AD in substance-induced psychotic 
disorders. One study of 121 patients with methamphetamine-induced psychosis reported 3.3% 
comorbidity with anxiety as measured by the Hamilton anxiety scale (HAM-A)11 and 24.8% with OCD 
as measured by the Yale-Brown obsessive compulsive scale12 (Y-BOCS).13    
 
In the local context, data is even sparser with only a few African and South African studies 
identified.8,10,14–18  Some South African literature has found potentially lower rates of obsessive 
compulsive disorder in schizophrenia amongst non-Caucasian participants10,16, but these findings 
require replication and reasons for it remain unknown. With the known high prevalence of anxiety 
disorders amongst the general population in South Africa19, more local data on anxiety comorbidity 
in psychotic disorders is needed. 
 
In the general population in South Africa, risk factors for anxiety disorders include female gender and 
lower educational levels.19  In local and international data of anxiety within psychotic illnesses, higher 
prevalence has been noted amongst women and younger patients, but this data is limited.8,20,21  
 
Accurate diagnosis in clinical practice and in research is often complicated due to overlapping 
symptom clusters and superficial similarities in presentation. In addition, both positive and 
negative symptoms of psychosis may mask anxiety as a result of the dramatic nature of positive 
symptoms and the effects of negative symptoms on emotional expressivity and communication.22  
Diagnosis may also be complicated by the hierarchical structure found in diagnostic systems such as 
the Diagnostic and Statistical Manual of Mental Disorders (DSM).23,24  Clinically, perhaps due to a 
combination of all these factors, anxiety disorders appear to be seldom recognised or treated in 
patients with psychotic illnesses.  
 
Anxiety disorders themselves are disabling and can be potentially life threatening.7  In addition, 
comorbid anxiety seems to have overall negative effects on outcomes of psychotic illness, including 
decreased levels of social functioning, worse quality of life, increased suicide risk, higher risk of 




It remains unknown whether anxiety in psychotic illness should be viewed as secondary to the 
distressing nature of psychosis and related experiences, as a comorbidity that occurs by chance, as a 
result of shared risk factors or whether anxiety features represent part of a prodromal picture or 
different symptom dimension of the core condition.1  A further complicating factor is that some 
neuroleptic drugs used in psychotic disorders have been associated with treatment-emergent 
anxiety symptoms.22,27–29   As patterns of comorbidity are increasingly understood, these may give 
clues into underlying neurobiology of both anxiety and psychotic disorders. 
 
Although not much is known about how best to treat comorbid anxiety in these populations, 
preliminary data has shown promising response to certain psychotherapeutic and pharmacological 
interventions.22,30–35  Successful treatment of anxiety could potentially improve outcomes in 
individuals with psychotic illness and is particularly topical considering the increasing recognition 
of the heterogeneity of psychotic illness, the rise of the recovery movement and more interest in 
individualising management.  
 
If more is known about the prevalence and correlates of AD in the various psychotic disorders, 
particularly in a South African context, clinical recognition, diagnosis and treatment of affected 
individuals may increase, ultimately improving outcomes. 
 
The primary aim of this study was to investigate the prevalence and correlates of anxiety disorders in 
psychotic illness in a sample of patients from Valkenberg Hospital. We aimed to determine the overall 
prevalence of comorbid anxiety disorders in a sample of patients with psychotic disorder diagnoses 
and to measure the prevalence of anxiety disorders for each of the different psychotic disorder 
diagnoses and compare these. In addition, we aimed to test the hypothesis that comorbidity of AD in 
psychotic illness would correlate positively with female gender, younger age and a lower level of 
education. 
 
Since collection of the data, the DSM-5 has been released, replacing the DSM-IV-TR. In DSM-5, OCD 
and PTSD were removed from the anxiety disorders chapter and selective mutism and separation 
anxiety were added. For the purposes of this study , the DSM-IV definition of anxiety disorders was 
utilised as the data was collected using SCID-I which includes OCD and PTSD as anxiety disorders 
but does not include selective mutism or separation anxiety.  
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2. Research methods and design 
2.1. Study design 
The study was a secondary analysis of an existing database. The original database was derived from 
a cross-sectional study investigating the psychobiology, presentation and risk factors in psychotic 
disorders, a pilot randomised trial of treatment partner interventions in people with serious mental 
illness and a neuroimaging study of psychotic disorders. 
 
2.2. Study setting 
The sample of 226 participants represented in the database was selected from adult inpatients and 
outpatients attending Valkenberg Hospital in Cape Town, South Africa and referral centres in its 
catchment area.  
 
Valkenberg Hospital is a state-funded psychiatric hospital which serves as a tertiary-level referral 
centre for the surrounding area of the Cape peninsula. The majority of the hospital’s 340 beds are 
dedicated to acute psychiatric services for the admission of individuals with severe mental illness, 
often as involuntary patients.  Both the hospital, and primary and secondary level healthcare facilities 
in its catchment area, provide various psychiatric outpatient services.  Valkenberg Hospital is 
affiliated with the University of Cape Town’s Department of Psychiatry and Mental Health, and 
functions as one of its main teaching hospitals.  
 
2.3. Study population and sampling 
The sample of patients represented in the database, includes participants from three previous clinical 
studies. The first study randomly sampled inpatients from Valkenberg hospital. The second study 
recruited inpatients with severe mental disorders attending the same hospital as part of a randomised 
trial investigating a treatment partner and text messaging interventions to improve adherence. 
Inclusion criteria for these studies were patients with a diagnosis of a psychotic disorder, including 
bipolar disorder type I with psychosis, schizophrenia, schizoaffective disorder, schizophreniform 
disorder, psychotic disorder not otherwise specified, and substance induced psychotic disorders. The 
third neuroimaging study recruited only outpatients with psychotic disorders (schizophrenia, bipolar 
and methamphetamine psychosis) via advertisements and referral from clinicians from the same 
clinical setting.  The age range for inclusion in all three studies was 18-65 years.  Participants were 
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required to be able to speak conversational English. Patients with a diagnosis of dementia or psychosis 
due to general medical condition were excluded in all three primary studies. Data was collected from 
Jan 2009 to April 2014. All patients provided written informed consent to participate in the original 
studies. The original and secondary data analyses studies were approved by the Human Research 
Ethics Committee of the University of Cape Town. 
Socio-demographic information was collected using a structured questionnaire. Clinical information 
and diagnosis was determined using the Structured Clinical Interview for DSM (SCID-I) 36, Modules 
A,B,C,D,E,F. Module F records anxiety symptoms and generates diagnoses of the various DSM-IV 
defined anxiety disorders (Panic disorder, generalised anxiety disorder, OCD, PTSD, simple phobia, 
social phobia).  Assessments were completed in English by psychiatrists and psychiatric nurses with 
extensive training and experience in SCID-I. 
 
2.4. Research procedure and data analysis  
The relevant variables were extracted from the database and tabulated. We used Pearson’s chi-
squared test or Fisher’s exact test where appropriate to analyse categorical data. We calculated the 
95% confidence intervals around prevalence rates using the normal approximation of the binomial 
distribution. We used two- tailed test with a significance levels of p<0.05 throughout. Statistical 
analysis was carried out using Stata version 13 for Windows. 
 
3. Results 
3.1. Sample characteristics 
The sample comprised 226 subjects, of whom 145 (64.16%) were male and 81 (35.84%) were female. 
The median age of the sample was 30, with a range between 18 and 61 years old.    The majority of 
patients in the sample (179, 79.2%) had never been married, and most (n=155, 68.58%) were 
unemployed. Ethnicity of patients in the sample was categorised into “Coloured” (n=128, 56.64%), 
“African” (n=62, 27.43%), “Caucasian” (n=27, 11.95%) and “Other” (n=6, 2.65%). For three patients in 
the sample (1.33%), ethnicity was not captured. The highest level of education was between Grade 8 
and Grade 11 for the majority of patients in the sample (n=112, 49.56%), with 34 (15.04%) having an 




Psychotic disorder diagnoses were divided into four categories: schizophrenia-spectrum, bipolar 
disorder, schizoaffective disorder and substance-induced mood or psychotic disorder. The 
schizophrenia-spectrum category comprised schizophrenia (n=106), schizophreniform disorder (n=5), 
psychotic disorder not otherwise specified (n=9) and brief psychotic disorder (n=1). This category 
totalled 121 patients, 53.54% of the sample. The bipolar disorder category (n=44, 19.47% of the sample) 
included only patients with bipolar disorder, type I with psychotic features. Schizoaffective disorder 
(n=30) comprised 13.27% of the total sample. The substance-induced mood or psychotic disorder 
category (n=31) was made up of substance-induced psychotic disorder (n=30) and substance-induced 
mood disorder (n=1) and constituted 13.72% of the sample. 
 
3.2. Prevalence and correlates of anxiety disorders 
The overall prevalence of any anxiety disorder in the entire sample was 14.6% (n=33), 95% CI [10.27-
19.89%]. There was a significant association between psychotic disorder diagnosis and the presence 
of PTSD, with the schizoaffective disorder group having a higher rate of PTSD (13.3% vs. 3.3% in SCZ 
and 3.2% in SIMPD and 0% in BPD-I) (Fisher’s exact test, p=0.039). In turn, there was a trend level 
association between psychotic disorder diagnosis and the presence of panic disorder (PD), with 
schizoaffective disorder patients having higher rates of PD (16.6% vs. 4.1% in SCZ spec, 3.2% in 
SIMPD and 2.2% in BPD_I)(Fisher’s exact test, p=0.052). (Table 1) 
 
The most common anxiety disorder comorbidities were, in descending order, panic disorder (n=12, 
5.31%; 95% CI [2.77-9.09%]), PTSD (n=9, 3.98%; 95% CI [1.84-7.42%]), specific phobia (n=7, 3.10%; 95% 
CI [1.25-6.28%]), anxiety disorder not otherwise specified (n=7, 3.10%; 95% CI [1.25-6.28%]), social 
phobia (n=4, 1.77%; 95% CI [0.48%-4.47%]), generalised anxiety disorder (n=4, 1.77%; 95% CI [0.48-
4.47%]), substance-induced anxiety disorder (n=4, 1.77%; 95% CI [0.48-4.47%]) and obsessive 
compulsive disorder (n=2, 0.88%; 95% CI [0.11-3.16%]).  
 
Associations of various sociodemographic variables with rates of comorbid anxiety disorders, were 
examined We found a significant association between level of education and the presence of PTSD, 
with higher rates of PTSD in patients with seven or less years of education (8.8%) compared to lower 
rates in those with 8-12 years of education (5.3%) and > 12years of education (0%)(Fisher’s exact test, 
p=0.020). (Table 2) 
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Table 1: Distribution of anxiety disorder comorbidity by psychotic disorder diagnosis 
 AAD GAD PD‡ OCD PTSD† SIAD Sp.P AD 
NOS 
 SP 
 n n n n n n n n n 
 (%) (%) (%) (%) (%) (%) (%) (%) (%) 
Total sample 33 4 12 2 9 4 7 7 4 
(14.6) (1.77) (5.31) (0.88) (3.98) (1.77) (3.1) (3.1) (1.77) 
SCZ spec 19 1 5 1 4 4 2 6 2 
(15.7) (0.83) (4.13) (0.83) (3.31) (3.31) (1.65) (4.96) (1.65) 
BPD I 7 2 1 0 0 0 1 1 2 
(15.91) (4.55) (2.27) (0) (0) (0) (2.27) (2.27) (4.55) 
SZA 6 1 5 1 4 0 3 0 0 
(20) (3.33) (16.67) (3.33) (13.33) (0) (10) (0) (0) 
SIMPD 1 0 1 0 1 0 1 0 0 
(3.23) (0) (3.23) (0) (3.23) (0) (3.23) (0) (0) 
*Abbreviations: AAD=any anxiety disorder, GAD=generalised anxiety disorder, PD=panic disorder, OCD= 
obsessive compulsive disorder, PTSD= post-traumatic stress disorder, SIAD=substance-induced anxiety disorder, 
Sp.P=specific phobia, AD NOS=anxiety disorder not otherwise specified, SP=social phobia, SCZ 
spec=schizophrenia spectrum, BPD=bipolar disorder I, SZA=schizoaffective disorder, SIMPD=substance-induced 
mood/psychotic disorder. 
† p=0.039, ‡ p= 0.052  
**Percentages calculated according to row totals for diagnostic category. 



















Table 2: Comparison of sociodemographic characteristics of patients with psychotic disorder and 
comorbid anxiety disorder 
**Abbreviations: AAD=any anxiety disorder, GAD=generalised anxiety disorder, PD=panic disorder, OCD= obsessive 
compulsive disorder, PTSD= post-traumatic stress disorder, SAID=substance-induced anxiety disorder, Sp.P=specific 
phobia, AD NOS=anxiety disorder not otherwise specified, SP=social phobia, M=male, F=female, HLOE=highest level of 
education, Gr=grade, Prev.=previously, cohab.=cohabiting, Empl.=employed, Unempl.=unemployed. 
*Percentages calculated according to row variables. 
† p= 0.020 
***Some patients had more than one anxiety disorder diagnosis, i.e each anxiety disorder category analysed separately 
Demographic variable AAD** GAD PD OCD PTSD† AD NOS Sp.P SP SIAD 
Age in 
years 































































































































































































































































































































In this study of a sample of patients with psychotic disorders, we found an overall prevalence of 
anxiety disorders of 14.6%. This is lower than what has been reported in previous literature of 
comorbid anxiety disorders in psychotic illness but comparable to that reported by the South African 
Stress and Health (SASH) study, which showed a lifetime prevalence of anxiety disorders of 15.8% 
for the general population in South Africa.19  Prevalence rates of individual anxiety disorders were 
also lower than previously published literature.  
 
Possible reasons for the lower prevalence in this study include use of the SCID-I, which employs strict 
diagnostic hierarchy rules and has been associated with lower rates of anxiety comorbidity20, that the 
majority of the sample were inpatients and likely in the acute phase of a psychotic illness, and no use 
of self-report questionnaires or other additional, anxiety-specific diagnostic instruments. Another 
possible explanation is that of geographical and/or ethnic differences in South African patients with 
a psychotic disorder.  
 
The most frequent comorbid anxiety disorders in our study were panic disorder and PTSD. This is 
out of keeping with other literature which has mostly found OCD and SAD to be the most common 
anxiety comorbidities in psychotic illness.  
 
One possible reason for higher rates of PTSD may be related to the high levels of violence, crime and 
trauma in South Africa.37–40  In addition, South Africa has a scarcity of health resources compared to 
first-world regions and this may have led to long periods of untreated psychosis, more exposure to 
trauma in the community while ill as well as in health-care settings e.g. over-crowded hospital wards 
increasing rates of assault.  
 
Some previous literature from South Africa in non-Caucasian patients has shown lower rates of OCD 
in patients with schizophrenia.10,16  It is unknown whether these differences are due to genetic, cultural 
or language differences or whether they represent problems of methodology e.g. problems in 
translation of rating scales. Considering that the majority of our sample was made up of non-
Caucasian patients, the same factors may have affected our results, leading to a relatively low 




In terms of comparison across psychotic disorder diagnoses, we found a significant association 
between schizoaffective disorder and the prevalence of comorbid PTSD and PD. In a previous study 
which compared anxiety disorders in different psychotic illnesses, a similar association was found.7 
In this study, significant differences of comorbid anxiety were found between psychotic disorders, 
with the highest rate of anxiety disorders in schizoaffective disorder (30.1%), followed by BPD 
(22.4%) and then schizophrenia (16.7%). The authors hypothesised that higher prevalence of anxiety 
disorders in schizoaffective disorder may be associated with more mood features. 
 
In assessment of previous literature, we hypothesised that comorbid anxiety disorders in psychotic 
illness may be associated with female gender, younger age and lower levels of education. We 
examined these as well as other socio-demographic variables in our statistical analyses. A significant 
association was found between prevalence of PTSD and less than eight years of education. This result 
is in keeping with findings from the SASH study which showed an association between anxiety 
disorders and an elementary level of education amongst the general population in South Africa.19   
 
Certain results of this study differ from international literature and yet have commonalities with other 
South African studies. This raises the possibility of geographical differences in prevalence of 
comorbid anxiety disorders in psychotic illness. These differences may, in turn, support hypotheses 
relating such comorbidity to the effects of shared environmental risk factors. For example, higher 
rates of trauma exposure in the South African population is a likely factor in the higher prevalence of 
comorbid PTSD found in this study.  
 
The lower prevalence rate of comorbid OCD is in keeping with other South African literature for non-
Caucasian cohorts. This highlights potential effects of genetic or cultural factors that may be protective 
against OCD in psychotic illness. Further research in this area would be valuable in further 
elucidating this relationship and to identify what these factors may be. 
 
Several limitations of this study need to be considered, due to it being a secondary analysis of an 




Data was originally collected for studies with different hypotheses, aims and objectives to the current 
study. Additionally, the number of participants was determined by requirements of the original 
studies and may not represent an optimum sample size for the current study. 
 
The exclusion of patients who were not able to converse in English as well as the administration of 
SCID-I in English may impact on the generalizability of the results.  
 
A large proportion of participants included in the database were recruited as inpatients from a tertiary 
psychiatric facility. This sample may not be generalizable to other populations and may be skewed 
towards individuals with more severe forms of the relevant disorders or who were experiencing or 
recovering from an acute episode of illness at the time of the study. 
 
Some correlations of anxiety in psychotic illness that have been described in the literature were not 
available for all participants in the current database. (E.g. history of childhood trauma, predominance 





Anxiety disorders have been shown to be a common comorbid problem for patients with psychotic 
illness and have negative effects on prognosis and outcome. Despite lower prevalence rates of 
comorbid anxiety disorders in our study, they remain a significant problem for some patients and 
have potentially far-reaching consequences.  
 
The rate of clinically-recognised comorbid anxiety disorders is likely to be even lower than prevalence 
reported in research settings due to diagnostic difficulties and lack of clinician awareness. Although 
ideal treatment strategies remain unknown, some early data is available to guide management of such 
patients. Increased awareness, routine screening for anxiety symptoms and use of ratings scales and 
self-report instruments when appropriate, may increase clinical recognition and diagnosis rates, 





Further research is needed, particularly in the South African setting and regarding appropriate 
treatment strategies. 
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